Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Insomnia: a major public health issue
National Sleep Day, which falls on March 17th, is an opportunity to highlight that nearly 60% of cancer patients suffer from insomnia during and after treatment. Non-pharmacological solutions exist for treating this disorder.
Published on
National Sleep Day, which falls on March 17th, is an opportunity to highlight that nearly 60% of cancer patients suffer from insomnia during and after treatment. Non-pharmacological solutions exist for treating this disorder.
A common symptom in oncology, insomnia can be associated with anxiety or memory problems and an increased risk of depression. Cognitive-behavioral therapy (CBT) is an effective non-pharmacological intervention for treating insomnia. However, it remains difficult for patients to access due to a lack of trained healthcare professionals in the area, the distance patients have to travel to access resources, and the impact of cancer-related symptoms and treatments on mobility.
To address these barriers, digital solutions and online care devices can help patients to access better care.
Online care program
The Sleep-4-all-2.0 study, led by Gustave Roussy with the participation of the Montpellier Cancer Institute and the Léon Berard Center, and funded by the National Cancer Institute, targets insomnia in oncology. It offers patients suffering from insomnia during or after treatment the opportunity to participate in the Insomnet program, which is based on cognitive-behavioral therapy. This online solution was scientifically constructed and validated by a team from Quebec.
To help patients suffering from insomnia to follow this program over time and to appropriate the techniques proposed, the Sleep-4-All-2.0 study provides reinforced support by a psychologist trained in the cognitive-behavioral approach, including the planning of systematic telephone interviews before, during, and at the end of this 6- to 12-week program. Its main objective is to explore for which patients, at what time, and in what form professional support is crucial to resolve insomnia. To date, 318 patients have already been included in the study
The results of this study will contribute to improving knowledge of how to support patients in facing these types of online therapeutic devices to better manage insomnia in oncology.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
